Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02172 微創腦科學
Listing Date2022/07/15
Listing Price24.640
  • 14.420 +0.060 (+0.418%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    25 lot
  • One Lot Success Rate

MicroPort NeuroTech is a China-based company in the neuro-interventional medical device industry. It amassed a total of 30 assets in its portfolio, including ten therapeutic products and three access products approved and commercialized in China and 17 product candidates under development.

Its therapeutic products covering all of the three major areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke (AIS).

The Group have commercialized products covering key therapeutic categories, including embolization coils, flowdiverting stents and stent grafts. In addition to approvals in China, NUMEN and NUMEN FR, two of flagship embolization coil products, have been approved in the United States, the European Union and South Korea. It plans to establish a R&D and production center in the United States.

According to CIC, the Group is the only Chinese company among the top five players in this market in terms of revenue in 2020, with a market share of approximately 4%.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot1000
No. of Offer Shares13.70M shares
No. of International Offer Shares9.59M shares
No. of HK Offer Shares4.11M shares
Offer Price$24.64
Stock Code2172
Sponsor(s)J.P. Morgan Securities (Far East) Limited, China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)J.P. Morgan Securities (Asia Pacific) Limited, China International Capital Corporation Hong Kong Securities Limited, Futu Securities International (Hong Kong) Limited, Livermore Holdings Limited
Application PeriodJun 29 (Wed) - noon, Jul 08 (Fri)
Price Determination Date--
Result Announcement DateOn or before Jul 14 (Thu)
Result Announcement DateOn or before Jul 14 (Thu)
Dealings in Shares commence onJul 15, 2022. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$24.64
NAV / share ($)$2.41 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 24.64, the net proceeds raised would be HKD 278.10M, of which
30% : Research and development of therapeutic and access products
20% : Commercialization of products
15% : Expansion of manufacturing facility to increase production
20% : Expanding global presence
10% : Advancing product portfolio through strategic acquisitions and investment
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.